Patents Assigned to UNIVERSITÄT BASEL
  • Patent number: 12208145
    Abstract: A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.
    Type: Grant
    Filed: February 21, 2023
    Date of Patent: January 28, 2025
    Assignees: Universität Basel, Paul Scherrer Institute
    Inventors: Cristina Müller, Roger Schibli, Nicholas Philip Van Der Meulen, Francesca Borgna, Damian Wild, Melpomeni Fani
  • Publication number: 20250018067
    Abstract: The invention relates to a hafnium (IV) oxide (HfO2) nanoparticle nanocrystal comprising or having a diameter equal or less than (?) 15 nm, stabilized by a plurality of dispersant molecules attached to its surface. The dispersant molecules comprise of a catechol or gallol surface adsorption moiety and an oligo (ethyleneglycol) moiety. The invention further relates to a composition of such nanoparticles in stable colloidal suspension at physiological pH, and the use of the composition in medical treatment and diagnostic applications, particularly to enhance radiotherapy and as an X ray contrast agent. In yet another aspect, the invention provides a method for manufacturing compositions and nanoparticles according to the invention.
    Type: Application
    Filed: November 23, 2022
    Publication date: January 16, 2025
    Applicants: UNIVERSITÄT BASEL, UNIVERSITEIT GENT
    Inventors: Loren DEBLOCK, Jonathan DE ROO
  • Patent number: 12196740
    Abstract: The invention relates to a method for classifying a tissue sample obtained from mammary carcinoma. The method comprises determining a stiffness value for each of a plurality of points on said tissue sample, resulting in a stiffness distribution, and assigning said sample to a breast cancer subtype and nodal status based on said stiffness distribution.
    Type: Grant
    Filed: June 26, 2023
    Date of Patent: January 14, 2025
    Assignee: UNIVERSITÄT BASEL
    Inventors: Marija Plodinec, Ellen Obermann, Philipp Oertle, Christian Räz
  • Publication number: 20240344031
    Abstract: A mesenchymal stem/stromal (MSC) cell line, in particular a human mesenchymal stem cell (hMSC), capable of chondrogenic differentiation when cultured in a chondrogenic medium, comprising a first transgene comprising a first nucleic acid sequence encoding for a preferably mammalian immortalizing enzyme under control of a first promoter sequence operable in said mesenchymal cell and a second transgene comprising a second nucleic acid sequence encoding a preferably mammalian bone morphogenic protein under control of a second promoter sequence operable in said mesenchymal cell.
    Type: Application
    Filed: August 2, 2022
    Publication date: October 17, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Sebastien PIGEOT, Ivan MARTIN, Paul BOURGINE
  • Patent number: 12091670
    Abstract: The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of heterologous proteins into eukaryotic cells.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: September 17, 2024
    Assignee: Universitaet Basel
    Inventors: Cécile Arrieumerlou, Simon Ittig
  • Publication number: 20240299582
    Abstract: The present invention relates to adenovirus-associated virus comprising an influenza-derived neuraminidase transgene, used alone or together with an immune checkpoint inhibitor to treat a patient diagnosed with a solid cancer.
    Type: Application
    Filed: February 18, 2022
    Publication date: September 12, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Heinz LÄUBLI, Natalia RODRIGUES MANTUANO
  • Publication number: 20240241099
    Abstract: The invention relates to a method of identifying selective covalently binding inhibitors by using a reversibly inhibiting scaffolds modified by a warhead comprising a fast-reacting Michael acceptor moiety and a linker of different length, determining kinact, and replacing the warhead of the covalently binding inhibitor with the highest kinact by a warhead comprising a moderately reacting Michael acceptor.
    Type: Application
    Filed: April 9, 2022
    Publication date: July 18, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Chiara BORSARI, Matthias WYMANN
  • Publication number: 20240226540
    Abstract: A novel ultra-thin neural implant (1) is provided that is based on a cellulose thin film (4) featuring an array (2) of electrodes (3). Due to the use of cellulose as the base material, the implant (1) can be safely handled during a micro-surgery, despite its high softness and conformability. Such an implant (1) may be useful in numerous applications ranging from electrical stimulation in neural prostheses, electro-stimulated regeneration of neural tissue to accurate recording of nerve signals. The robustness of the implant (1) results from a woven fabric (5) that is integrated in the cellulose carrier thin film (4). Several approaches for enhancing the tissue compatibility of the implant (1) are also provided.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 11, 2024
    Applicant: Universität Basel Vizerektorat Forschung
    Inventors: Bekim OSMANI, Tino TÖPPER, Bert MÜLLER, Carina LUCHSINGER SALINAS, Raphael GUZMAN, Alois HOPF, Mahyar JOODAKI
  • Publication number: 20240217960
    Abstract: Kinase-targeted covalent inhibitors are usually irreversibly targeting noncatalytic cysteines in the ATP-binding site. These compounds are designed by directly introducing an electrophile on a reversible-inhibitor scaffold. Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads), targeting a solvent exposed cysteine at >10 ? from the core reversible inhibitor. A variety of novel linkers have been designed and used to link the warhead with the reversible scaffold. We disclose a novel chemical space for drug-like covalent modifiers of phosphoinositide 3-kinase alpha (PI3K?), an enzyme frequently altered in human malignancies. The invention relates to novel covalent inhibitors showing higher in vitro affinity, cellular potency and improved metabolic stability (rat liver microsomes).
    Type: Application
    Filed: April 9, 2022
    Publication date: July 4, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Matthias WYMANN, Chiara BORSARI
  • Publication number: 20240208957
    Abstract: Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads) and behaving as reversible and irreversible covalent inhibitors. Linkers have been introduced to target a solvent exposed, distal cysteine at >10 ? from the core reversible inhibitor. Different exit vectors have been investigated to modulate inhibitor intrinsic reactivity and efficiency in covalent bond formation. We disclose novel, optimized covalent modifiers of phosphoinositide 3-kinase alpha (PI3K?), an enzyme frequently altered in human malignancies. The compounds of the invention could be exploited as therapeutic agents and chemical probes useful for the investigation of the role of PI3K isoforms in cancer and metabolism, and for treatment of PI3K?-driven cancers and malformations.
    Type: Application
    Filed: April 9, 2022
    Publication date: June 27, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Chiara BORSARI, Matthias WYMANN
  • Patent number: 11992467
    Abstract: The present invention refers to lipophilic extracts of members of the Iridaceae family, such as Iris germanica and/or Iris pallida, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas. The most active components were found to be the iridals.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: May 28, 2024
    Assignees: Universitaet Basel, Eth Zuerich
    Inventors: Michael Detmar, Matthias Hamburger, Olivier Potterat, Adriana Sliwa-Primorac
  • Patent number: 11982580
    Abstract: For improving the sensitivity, lifetime and energy consumption of a dielectric elastomer transducer (1) to be used as a sensor, it is suggested that a dielectric layer (3) enclosed by two electrodes (2) of the transducer (1) includes a nanoscale volume of a fluid (15) such that the dielectric layer (3) is rendered compressible and/or displaceable out of a volume enclosed by the two electrodes (2). The advantage of such a design is that, although the dielectric layer (3) and possible buffer layers (4) separating the electrodes (2) from the dielectric layer (3) may all have thicknesses in the order of a few ?m or even in the sub-?m range, the transducer (1) is rendered highly compliant due to the movability of the fluid (15). In consequence, a large nominal capacitance of the transducer (1) as well as a large relative capacitance change (up to twenty times that of the nominal capacitance) can be achieved in conjunction with a very high sensitivity.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: May 14, 2024
    Assignee: Universität Basel Vizerektorat Forschung
    Inventors: Tino Topper, Bekim Osmani, Bert Mueller
  • Patent number: 11904051
    Abstract: A liposome vesicle comprising a membrane consisting of 1,3-diheptadecanamidopropan-2-yl(2-(trimethylammonio)ethyl)phosphate surrounding a volume comprising a pharmaceutical drug or contrast agent. The vesicle is mechanosensitive at body temperature and at physiologically or pathophysiologically relevant shear stress.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 20, 2024
    Assignees: Universität Basel, Universität Freiburg
    Inventors: Bert Müller, Andreas Zumbühl, Thomas Pfohl, Dennis Müller, Frederik Neuhaus, Radu Tanasescu, Till Saxer, Marzia Buscema, Sofiya Matviykiv, Gabriela Gerganova
  • Patent number: 11896707
    Abstract: The present invention relates to the use of plant extracts from the genus Daphne for the cosmetic treatment of the skin and to cosmetic preparations which comprise extracts of Daphne giraldii and/or Daphne gnidium or other members of the genus Daphne containing daphnetoxin and/or other daphnane diterpenoids for skin treatment. The plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: February 13, 2024
    Assignees: ETH Zurich, Universität Basel
    Inventors: Michael Detmar, Epameinondas Gousopoulos, Olivier Potterat, Jihye Kim, Adriana Sliwa-Primorac, Antonia Elisabeth Schantl, Maria Teresa Faleschini, Matthias Hamburger
  • Patent number: 11878972
    Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (iii) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalk
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: January 23, 2024
    Assignees: TORQUR AG, UNIVERSITÄT BASEL
    Inventors: Denise Rageot, Paul Hebeisen, Florent Beaufils, Doriano Fabbro, Petra Hillmann-Wüllner, Hoa Huu Phuc Nguyen, Wolfgang Löscher, Claudia Brandt, Alexander Markus Sele
  • Publication number: 20240010682
    Abstract: The present invention relates to a hemostatic elastin-like polypeptide comprising a glutamine embedded in a Q-block sequence and, optionally, a lysine embedded in a K-block sequence. Under physiological setting, the Q-block sequence and the K-block sequence are recognized by human transglutaminase factor XIIIa and crosslinked with fibrin networks. The present invention also relates to the medical use of the polypeptide, to a nucleic acid sequence encoding the polypeptide, to an expression vector comprising the nucleic acid sequence, and to a cell comprising the nucleic acid sequence or the expression vector.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 11, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Michael Adam NASH, Ivan UROSEV
  • Publication number: 20240002465
    Abstract: Described herein is a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 4, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Gennaro DE LIBERO, Marco LEPORE, Lucia MORI
  • Patent number: 11807676
    Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: November 7, 2023
    Assignees: UNIVERSITÄT ZÜRICH, UNIVERSITÄT BASEL
    Inventors: Osiris Marroquin Belaunzaran, Christoph Renner
  • Publication number: 20230353350
    Abstract: The invention relates to a method for device-independent quantum key generation and distribution between a first and a second receiver, the method comprising the steps of: a) Generating an entangled information pair, comprising two entangled quantum moieties that have at least one quantum state entangled with each other, such as a polarization, b) Transmitting a first entangled quantum moiety of the two entangled quantum moieties to the first receiver (A) and a second entangled quantum moiety of the two entangled quantum moieties to the second receiver (B), and measuring the quantum states of the entangled moieties with a set of selected detection settings chosen randomly at each receiver c) In a modification step, assigning each measurement value b1 measured with a detection setting B1 a complementary value b 1 ? according to a noise-probability p, wherein the noise-probability p is larger than 0 and lower than 1, such that a modified plurality of measurement values b 1 ˜ is obtained
    Type: Application
    Filed: May 12, 2021
    Publication date: November 2, 2023
    Applicants: ETH ZURICH, UNIVERSITÄT BASEL
    Inventors: Melvyn HO, Pavel SEKATSKI, Jean-Daniel BANCAL, Nicolas SANGOUARD, Ernest TAN, Renato RENNER
  • Publication number: 20230344201
    Abstract: The present invention relates to a single photon source, comprising: a microcavity arranged between a concave first minor and a semiconductor heterostructure forming a planar second minor, wherein the microcavity supports an optical mode, a quantum dot embedded in the semiconductor heterostructure and facing the first minor, and a laser light source configured to provide laser light in the microcavity to excite the quantum dot to emit single photons exiting the microcavity.
    Type: Application
    Filed: July 15, 2021
    Publication date: October 26, 2023
    Applicant: UNIVERSITÄT BASEL
    Inventors: Richard J. WARBURTON, Alisa JAVADI, Daniel NAJER, Natasha TOMM